UniQure Shares Drop 67% After FDA Questions Huntington’s Disease Therapy
TL;DR Summary
UniQure's plans to submit its Huntington's disease gene therapy, AMT-130, for FDA approval are now uncertain after the agency indicated it no longer considers existing data sufficient, marking a significant shift from previous communications and causing a 60% drop in the company's premarket shares.
- UniQure’s FDA submission for its Huntington’s disease therapy thrown into question statnews.com
- UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy Reuters
- uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease Yahoo Finance
- uniQure stock plummets after FDA shifts stance on Huntington’s therapy Investing.com
- UniQure Stock (QURE) Plummets 67% on FDA News. Here’s Why. Barron's
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
81%
234 → 44 words
Want the full story? Read the original article
Read on statnews.com